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liberte), 90 zotarolimus (ZES; Endeavor) and 421 everolimus eluting stents (EES;
Xience-V & Promus). Initial follow-up angiography was performed at 8 months after
stenting in all patients, and long-term follow-up angiography at 2 years was performed in
patients not exhibiting initial restenosis.
Results: The initial restenosis was 23.3% for BMS, 6.7 for SES, 14.8 for PES, 13.3 for
ZES and 6.7 for EES. Thus, the restenosis rate of BMS was significantly greater than that
in DESs (p0.0001). Interestingly, the initial restenosis of SES and EES were smaller
than those of other DESs. In contrast, long-term restenosis were 7.1% for BMS, 10.7 for
SES, 7.2 for PES, 4.0 for ZES and 2.9 for EES, yielding no significant differences between
them except EES. In late followed study, late loss at 8-months/2-years was 0.76/0.80mm
for BMS, 0.18/0.48 for SES, 0.40/0.49 for PES, 0.60/0.43 for ZES and 0.23/0.32 for EES.
The serial change of late loss in SES was significantly increased and this increase affected
the deterioration of late restenosis in SES.
Conclusions: These results demonstrate that in comparison with BMS, stent-related late
restenosis could not be improved by SES, PES and ZES, probably due to late catch-up
phenomenon associated with inflammation-related neo-atheroslcerosis. But EES could
improve late-catch-up restenosis. We suggest careful long term follow-up of patients who
had DES implation even without intial restenosis.
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Background: Compared to larger vessels percutaneous coronary intervention (PCI) of
small vessel coronary artery disease presents technical challenges and a greater risk for
restenosis, stent thrombosis, and major adverse cardiac events. The long term safety and
effectiveness of drug-eluting stents for small vessel lesions therefore remains a concern.
Methods: Patients with a broad range of clinical and lesion characteristics undergoing
PCI with a Resolute zotarolimus-eluting stent (R-ZES) in small vessels (reference vessel
diameter [RVD] 2.5 mm) were pooled from 5 trials: RESOLUTE All Comers,:
RESOLUTE first-in-human, RESOLUTE International, RESOLUTE Japan, and RESO-
LUTE US. Dual antiplatelet therapy was prescribed for 6 months and at operator
discretion thereafter. Safety and effectiveness endpoints; target lesion failure (TLF;
composite of cardiac death [CD], target vessel myocardial infarction [TVMI], or
clinically-driven target lesion revascularization [TLR]), CD, TVMI, CD or TVMI, TLR,
and definite or probable stent thrombosis (ST) were compared between patients with small
and large vessels (RVD 2.5 mm) after propensity score adjustment for differences in
baseline characteristics.
Results: There were 1956 patients (38.1%) with a RVD 2.5 mm and 3174 patients
(61.9%) with RVD 2.5 mm. Most baseline characteristics were significantly different
between the 2 groups; small vessel patients were older with a higher proportion of females
and had higher rates of diabetes, prior PCI, hypertension, hyperlipidemia, and multivessel
disease.







TLF 10.1% 8.7% 0.535
Cardiac death 2.0% 2.4% 0.668
TVMI 3.9% 3.2% 0.380
CD or TVMI 5.7% 5.2% 0.488
Clinically-driven TLR 5.3% 4.4% 0.341
ST (def/prob) 0.8% 1.0% 0.288
- early (30 d) 0.5% 0.6% 0.550
- late (31-360 d) 0.3% 0.2% 0.360
- very late (360 d) 0.1% 0.2% 0.283
Conclusions: After adjustment for differences in baseline characteristics there are no
significant differences in safety and effectiveness outcomes to 2 years between patients
with large and small vessel disease. The rates of CD, TVMI and ST provide evidence for
the long-term safety of R-ZES in patients regardless of RVD.
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Background: Recent data suggest that late or very late stent thrombosis (ST) is
associated with lower in-hospital mortality than early ST, but data on longer-term
outcomes is lacking.
Methods: Data from the VHA Cardiovascular Assessment, Reporting, and Tracking
(CART) Program was used to identify all presentations of angiographic ST with known
timing between 2006-2011 at 76 VA hospitals. In accord with the Academic Research
Consortium (ARC) standards, cases occurring  30 days after stent implantation were
defined as early; 31-365 days as late; and  365 days as very late. Cox-proportional
hazard regression modeling with backwards covariate selection was used to describe
differences in mortality rates after ST.
Results: A total of 448 patients with ST and known time from initial stent implantation
were identified. The cohort consisted of 124 (28%), 96 (21%), and 228 (51%) patients
with early, late and very late ST, respectively. Late and very late ST were associated with
lower crude mortality than early ST at both 30-days and 90-days (Figure). On multivariate
modeling, patients with very late ST had significantly lower 30-day mortality (HR 0.3,
[95% CI 0.13-0.68]) when compared to patients with early ST. Similar trends were also
observed for late ST compared to early ST.
Conclusions: Long term mortality risk following an angiographic ST presentation differs
as a function of time from index PCI to ST, potentially reflecting the differing mechanisms
of ST that predominate at different timeframes. Specifically, ARC very late ST is
associated with lower mortality at 30 days when compared to early ST.
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Background: There are no observational studies directly comparing the safety and
efficacy of balloon angioplasty (POBA) versus DES for treatment of DES in-stent
restenosis (ISR).
Methods: We examined data on all patients who underwent percutaneous coronary
intervention (PCI) for ISR at Toyohashi Heart Center between 01/2004 and 05/2012. We
compared the efficacy of DES to balloon angioplasty for treating DES ISR.
Results: Of the 9126 patients who underwent PCI treated with DES over 8 years, 512 had
DES ISR and met our study criteria. Of the 353 patients with DES ISR, were treated with
balloon angioplasty and 129 with DES. At 1-year angiographic follow-up (follow-up rate:
73%), in-stent restenosis was observed in 117 cases in the POBA group and 28 cases in
the DES group (45% vs. 30%; P  0.017). In a comparison between treatments using a
cutting balloon vs. a conventional balloon, there was no significant difference observed in
the rate of angiographic restenosis.
Conclusions: In our analysis of patients with DES ISR, DES use was associated with a
significantly lower rate of ISR or TLR when compared to POBA.
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